Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

November 3, 2022

NASDAQ US Health Care Life Sciences Tools and Services earnings 60 min

Earnings Call Speaker Segments

Sallilyn Schwartz

executive
#1

Hi, everybody, and thanks for joining the earnings call for 2022's third quarter. On today's call, we'll go over the financial results that were issued following the market close, and we'll also give you our thoughts about commercial activity, and after that we'll open things up for questions and answers. If you weren't able to look at the earnings release yet, you can find it on our website, illumina.com, under the Investor Relations section. Here for Illumina today are Francis deSouza, our President and Chief Executive Officer, and Joydeep Goswami, our Chief Strategy and Corporate Development Officer, who is also serving as Interim Chief Financial Officer. Francis is going to give an update on how Illumina's business stands, and Joydeep will walk through our financial results, GRAIL included. One reminder: while the European Commission's investigation into Illumina's purchase of GRAIL is still pending, that commission has issued an order that calls for Illumina and GRAIL to be kept and run as two separate, distinct entities during an interim period. An independent monitoring trustee oversees whether the order is being followed. While this period lasts, Illumina and GRAIL may not share confidential business information unless the law requires it, and GRAIL has to operate independently and solely in GRAIL's own best interest. Any commercial dealings between the 2 companies have to happen at arm's length. This call is being recorded, and the audio portion will be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity that are made on today's call to be protected by the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results could differ materially from what is projected or discussed. All forward-looking statements rest on information currently available, and Illumina has no obligation to update these statements. To get a better understanding of the risks and uncertainties that might cause actual results to differ, please see the documents Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K; with that, I'll hand the call over to Francis.

Francis deSouza

executive
#2

Thank you, Sally, and hello to everyone this afternoon. Illumina's revenue for Q3 came to $1.1 billion, which works out to 1% growth over the same period a year ago, or 3% growth when measured on a constant currency basis — right in line with our forecast, even amid worsening macroeconomic conditions. Now for platform results in Q3: on the high throughput side, we delivered 65 NovaSeq 6000 systems this quarter, down from the previous year yet in keeping with what we expected. Customer reaction to the NovaSeq X Series unveiling at the Illumina Genomics Forum was extraordinary, and more than 12,000 viewers tuned in to our innovation road map sessions. NovaSeq X has generated a lot of excitement among labs, who praise its top-tier performance, productivity, and affordability. As they put it, they're thrilled by its surprising, game-changing sustainability advances—ambient temperature shipping among them, plus a 90% cut in the weight of packaging and the waste it creates. Demand from customers for NovaSeq X has come in higher than our forecasts. Beyond the 50 orders already received, we now have a substantial pipeline exceeding 170 instruments. Ramping up production is proceeding without issues, and our projection is to deliver 40 to 50 NovaSeq X units during Q1 2023, with more than 300 units across the full year. Additionally, at the Illumina Genomics Forum, we unveiled the NovaSeq 6000 DX—the first high-throughput sequencer to hold both FDA registration and a CE mark as an IVD. We're excited that DX products now span the full range of throughput levels. In the mid-throughput category, we set a record for NextSeq 1000 and NextSeq 2000 shipments, with a 40% increase compared to the prior year. That growth was driven by faster uptake of multiomics, primarily in cancer research along with cellular and molecular biology, spanning both new and existing customers. Also, as we continue executing our innovation road map, bringing XLEAP-SBS chemistry to NextSeq 1000 and NextSeq 2000 is still slated for 2024. Finally, shipments in the low-throughput segment were up 13% versus a year ago. Demand for these tools remains a strong way for people to get started with sequencing. That steady appetite for our platforms, spanning every level of throughput, should grow the installed base and fuel consumables sales down the road. Early access customers using Illumina complete long reads, as well as complete long reads with enrichment, are giving us encouraging responses, and we're adding more customer sites. What customers appreciate is Illumina's distinctive capacity to provide a complete, high-quality, cost-effective picture of the genome from one platform, which boosts value throughout our installed base. Now turning to market segments: clinical sequencing consumable shipments climbed 5% versus a year ago, driven by ongoing expansion in oncology testing and genetic disease testing. Among our clinical customers, sequencing run activity continues to be strong. That said, the delays in expanding labs and the reduction of consumables inventory—both of which we anticipated—have continued because of wider macroeconomic forces. Revenue from consumables used in oncology testing rose 9% compared with the same period last year, driven by bigger clients moving further toward high-throughput workflows, decentralized clinical testing customers increasing their activity, and the addition of new accounts. TSO 500, our TruSight Oncology assay that leads the market, posted 17% growth versus a year earlier, since major customers are capitalizing on what the assay offers in terms of utility, reimbursement, and proficiency. More and more users keep adopting TSO 500, with total accounts approaching $500 million. On the oncology side as well, GRAIL maintained strong momentum in Q3, generating clinical data and attracting a broad range of customers across the health care ecosystem, including health systems and life insurance providers. GRAIL announced a unique collaboration with Karim Health, which is the first digital health firm, connecting employers and their workers to centers of excellence through a value-based care platform. As part of this collaboration, Galleri gets offered within Karim's oncology services to self-insured employers. Also, John Hancock, Manulife's U.S. arm, which has more than 1.5 million life insurance participants, recently turned into the first life insurance provider to make Galleri available. During Q3, the GRAIL team grew its clinical sales force, and test orders have risen. Support for Galleri's effectiveness keeps expanding too; at ESMO in September, GRAIL shared strong final findings from its PATHFINDER study. According to the study, adding Galleri multi-cancer early detection testing to standard of care screening resulted in more than twice as many cancers found than with standard screening by itself. In fact, the number of cancers Galleri picked up exceeded the total from all single cancer screenings recommended by the U.S. Preventative Services Task Force when combined. Additionally, Galleri's positive predictive value comes in at roughly 40%, which is far above that of frequently used screening tests — for example, the annual colorectal cancer screen, with a PPV of 8.7%, or biennial mammography screening, at 4.4%. On the market today, Galleri stands as the sole multi-cancer detection test available. When the first 38,154 Galleri commercial test results were analyzed in a real-world setting, they showed strong concordance with what the PATHFINDER study found. Also, people in the PATHFINDER study who had experience with the Galleri test gave it positive marks as well — 97.1% of them said they were highly satisfied with it. On the genetic disease testing side, shipments of sequencing consumables rose 11% compared with the same period a year earlier. More and more geographies — EMEA and China among them — are boosting national health system funding for rare diseases, and the body of evidence keeps expanding. Take September, when Genetics in Medicine ran a study out of Karolinska Institute showing that genome sequencing works as a sensitive first-line test for neurodevelopmental disorders; beyond that, customers are excited about how NovaSeq X might drive efficiencies in both whole genome and whole exome sequencing. Now let's move to our research and applied markets. On the consumables side for sequencing, shipments fell 8% compared with the same period a year earlier. Customers are still keeping a tight grip on inventory and capital spending, and we also faced the headwinds we had anticipated from COVID surveillance plus the wrap-up of the UK Biobank project during the third quarter of 2021. Through all of these shifts, we remain committed to standing behind our customers, while steadily moving forward in making genomic-based drug discovery easier. With this field expanding, we intend to work alongside a variety of pharma companies — our newly announced collaboration with AstraZeneca is one example — to speed up genomics and identify attractive drug targets rooted in omic insights. Over in our infectious disease and microbiology markets, we are widening genomic possibilities spanning multiple disease states. To illustrate, we just shared news of an alliance with GenoScreen aimed at assisting nations dealing with tuberculosis in better identifying and fighting multidrug resistant strains. Each year, TB takes over 1.5 million lives, and following the pandemic, fatalities are increasing for the first time in 10 years. Through this effort, we aim to support at-risk groups and move closer to wiping out TB globally. Now shifting to the close of 2022 and moving into 2023. We anticipate the macroeconomic hurdles we've talked about before will continue through 2023, and we believe it makes sense to modify our short-term guidance as a result. Joydeep will soon cover our updated FY '22 guidance. Even with the tough macroeconomic conditions ahead in the near term, our confidence in long-term growth remains strong. Clients everywhere keep expressing enthusiasm about our newest developments. We're concentrating on backing them and pushing forward our innovation plans to speed up the genome era. At this point, I'll hand things over to Joydeep for further specifics on the quarter and our outlook for the year's end.

Joydeep Goswami

executive
#3

Appreciate that, Francis. Just to note, the third quarter financial results we're reporting reflect GRAIL on a consolidated basis. I'll begin with a look at our consolidated results, then move through the segment performance for core Illumina and GRAIL, and wrap up with some further comments regarding how we see 2022 shaping up. The figures I'll cover are non-GAAP, and they factor in stock-based compensation. Please take a look at the GAAP reconciliation for these non-GAAP measures, which you'll find in the earnings release issued today as well as in the supplementary data posted on our website. Consolidated revenue for the third quarter came to $1.12 billion, which represents a 1% increase versus the prior year, or 3% in constant currency terms, net of hedging effects. As we had anticipated, growth in our core business took a hit from expected headwinds tied to supply chain challenges at our customers that pushed back lab expansions, along with tighter inventory and capital discipline on the customer side given the difficult macroeconomic backdrop, including inflation and the unfavorable FX impact. Those dynamics carried on and in certain instances intensified as we moved through the third quarter, which is what drove us to lower guidance for the full year 2022, and I'll get into that later in my comments. For the third quarter, GAAP net loss totaled $3.82 billion, equating to a net loss of $24.26 per diluted share, and that figure includes a goodwill impairment of $3.91 billion tied to the GRAIL segment, driven mainly by the adverse effect of present capital market conditions and elevated discount rates, among them a stand-alone risk premium factored into the fair value calculation for the GRAIL segment. Non-GAAP earnings came in at $54 million, or $0.34 per diluted share, and that includes dilution from GRAIL's non-GAAP operating loss of $148 million during the quarter. Our non-GAAP tax rate stood at 43.2%, up from 25.8% in the prior quarter and 13.2% in Q3 2021, largely because of the greater impact of R&D expense capitalization requirements put in place by the Tax Cuts and Jobs Act of 2017. Our non-GAAP weighted average diluted share count for the quarter was roughly $159 million. Turning to segment results. I'll kick things off with Core Illumina's financial performance. Core Illumina revenue reached $1.11 billion, roughly flat compared with a year ago, or up 3% in constant currency terms, net of hedging effects. Core Illumina sequencing consumables revenue was $725 million, also approximately flat versus the prior year. As we expected, growth from a larger installed base was offset by the year-over-year effects of customer inventory and cash management, foreign exchange headwinds, the wrap-up of the U.K. Biobank project in quarter 3 of 2021, and the anticipated decline in COVID surveillance revenue. Sequencing activity on our connected instruments among clinical customers continues to be robust. Although the pace of research involving sequencing activity was held back by the various macroeconomic pressures Francis referenced. Sequencing instruments revenue for Core Illumina fell 10% year-over-year to $162 million, driven by fewer NovaSeq shipments resulting from expected delays in customer lab expansions and capital management, as well as purchasing delays ahead of next year's availability of NovaSeq X. This decrease was partly counterbalanced by all-time-high shipments of NextSeq 1000 and NextSeq 2000 units, which rose 40% compared with the prior year as adoption stays robust among customers new to Illumina. In Q3, COVID surveillance accounted for roughly $28 million of total revenue, made up of $23 million from sequencing consumables plus $5 million from instruments. That matched what we had anticipated and fell almost 50% versus a year earlier, owing to fewer testing samples and reduced instrument shipments, since COVID surveillance capacity had mostly been put in place during 2021. Core Illumina sequencing service and other revenue reached $123 million, climbing 12% from the same period last year, mainly because of greater instrument service contract revenue tied to a larger installed base along with higher core licensing revenue. Turning to Core Illumina's regional performance. The Americas brought in $592 million, a 2% year-over-year gain, largely fueled by NovaSeq consumables growth from demand among genetic testing, oncology testing and cancer research customers. As we anticipated, regional growth was mostly offset by delayed customer lab expansions plus inventory and capital management, along with a drop in COVID surveillance revenue. EMEA revenue came to $290 million, down 7% year-over-year, or down 2% in constant currency terms after accounting for hedge effects. Robust growth in mid-throughput instrument shipments from clinical demand was more than outweighed by the U.K. Biobank program finishing and a reduction in COVID surveillance revenue. Greater China revenue totaled $133 million, an increase of 9% year-over-year, or 14% in constant currency. A quarterly record for the region was propelled by growth in sequencing consumables for routine NGS-based research, which picked back up once the COVID restrictions that started in March this year were removed, plus solid NovaSeq 6000 sales mainly to clinical customers for oncology testing. We still anticipate base business growth will face headwinds from the 0 COVID-19 policy, exchange rates and slowing GDP growth in that region. Lastly, APG revenue of $95 million was up 6% year-over-year, or 10% in constant currency, net of hedge effects. Regional growth came from strong demand in emerging markets, particularly India, Indonesia and Thailand, and ongoing strength in NIPT and oncology testing. Now to the remainder of the Core Illumina P&L. Core Illumina non-GAAP gross margin was 68.9%, a decline of 240 basis points year-over-year, chiefly from reduced fixed cost leverage on lower manufacturing volumes and increased freight costs, partly offset by a favorable product mix. Core Illumina non-GAAP operating expenses totaled $514 million, an increase of $36 million year-over-year, mainly from headcount growth in the investments we're making in R&D to support continued advancements along our innovation road map. Even with that year-over-year rise, non-GAAP Core Illumina operating expenses came in about $25 million below our original plan. This stems from lower performance-based compensation expense given our reduced revenue outlook, as well as cost containment efforts centered on prioritizing hiring and discretionary spend, including travel. Now turning to GRAIL's financials. The $10 million in revenue that GRAIL brought in during the quarter came mostly from fees for the Galleri test. Non-GAAP operating expenses at GRAIL reached $149 million for the quarter, driven largely by costs tied to headcount and clinical trials. Shifting to consolidated cash flow and balance sheet matters. Operations consumed $52 million in cash, with the net outflow stemming from a onetime payment tied to the BGI litigation settlement we told you about last quarter. DSO came in at 51 days, up from 50 days in the prior quarter, reflecting revenue linearity. Capital expenditures for the third quarter of 2022 totaled $67 million, while free cash flow was negative $119 million. No common stock was repurchased during the quarter. We closed the quarter holding roughly $1 billion across cash, cash equivalents and short-term investments. Turning to 2022 guidance; our expectation now is that full year 2022 consolidated revenue will be flat to up 1% year-over-year, which includes core Illumina revenue that is approximately flat versus 2021 and GRAIL revenue falling between $55 million and $65 million. This revised full year outlook takes into account the tougher expected macroeconomic headwinds that we saw through October.

Joydeep Goswami

executive
#4

When it comes to core Illumina, roughly one-third of the cut to our 2022 guidance versus what we had previously anticipated comes mainly from pushed-back enrollment in certain sizable research programs across the Americas and Europe, plus inflation's effect on research customers in Europe. The other two-thirds of that cut breaks down about 70 to 30 between 2 factors that came in above what we expected. First, postponed purchases of instruments and consumables, largely because of the enthusiasm surrounding NovaSeq X; and second, unfavorable FX movement along with consumables inventory deleveraging. Looking at the whole year, we now anticipate core Illumina sequencing revenue will be roughly level compared with a year ago. That still incorporates intercompany sales to GRAIL of about $25 million, which get eliminated in consolidation. Inside core Illumina sequencing revenue, we now anticipate instrument revenue will decline modestly versus a year ago while consumables revenue stays roughly level, which mirrors NovaSeq pull through coming in a bit under our guidance range of $1.1 million to $1.2 million per system for 2022, mostly because of enrollment difficulties at certain sizable research and PopGen customers. Our other pull-through ranges remain consistent with the historical guidance ranges we've given before; for full year 2022, we now anticipate consolidated non-GAAP operating margin between 9.5% and 10%, and core Illumina non-GAAP operating margin of about 23%, mirroring our reduced revenue outlook. We anticipate a consolidated non-GAAP tax rate of about 7%, which still presumes that the R&D expense capitalization requirements put in place by the Tax Cuts and Jobs Act of 2017 will be repealed in Q4. We now anticipate non-GAAP earnings per diluted share between $2.35 and $2.50, which factors in a smaller than previously anticipated non-GAAP operating loss dilution from GRAIL of about $600 million. Finally, we still anticipate diluted shares outstanding of about 159 million shares for 2022. We anticipate the macroeconomic headwinds we're facing will carry on into 2023. As we mentioned on our prior earnings call, we're actively and carefully controlling operating expenses while keeping our focus on sustainable long-term revenue growth; we're well positioned to grab opportunities to scale in key areas that match customers' future needs and our innovation road map. Simultaneously, you'll see us pick up additional scale and efficiencies from other areas; we'll keep adjusting our investments and expenses to support our customers, push further progress in the genomics industry and make our long-term growth possible. I'll now turn the call back to Francis for his closing remarks.

Francis deSouza

executive
#5

Appreciate that, Joydeep. Like Joydeep mentioned, we'll keep looking for ways to lessen the short-term impacts coming from the worldwide economic climate. Meanwhile, our innovation road map sits at the top of our priorities, and our confidence in the long-term growth path remains strong. As I noted before, the feedback on what we unveiled at the Illumina Genomics Forum has been extremely positive — everything from Illumina complete long reads to the NovaSeq X Series, our strongest and most sustainable sequencer to date. The genomics field will keep being reshaped by these developments, and looking ahead, we hold enormous optimism for the long haul. Together, we'll guide our customers through today's difficulties and capture what the genome era can offer. At this point, I'd like to ask the operator to open the line so we can take questions.

Dan Brennan

analyst
#6

There's a lot we might get into, but I think I'll focus on the NovaSeq X and that 300-unit shipment target, which factors in the 50 units during 1Q that came in above what we had modeled. Francis and Joydeep, could you maybe share some detail about the customers and what early activity looks like? When it comes to orders, what's the split between bigger research buyers such as genome centers and the smaller ones on the clinical side? Also, taking into account those 50 orders you have, plus the 170 you brought up for the advanced order book, that puts you past 200 now. With the order momentum you anticipate building over the coming 6 to 9 months, would you call the 300 shipments—attractive as they are—perhaps on the conservative side?

Francis deSouza

executive
#7

Thanks, Dan, happy to address that. Let me take these one at a time. To start, you're absolutely correct that the customer reaction to NovaSeq X has been extremely strong, and it has us very pleased. In fact, it exceeded what we'd anticipated, and our expectations were already elevated when we went into the Illumina Genomics Forum. Buyers span a wide range of customer types. Alongside the genome centers you'd typically think of as early adopters, we're now seeing a greater mix from clinical. Our customer base also blends those located in the U.S. with those based outside it. So it's a good broad sampling of early adopters, and the clinical share may be slightly larger than what we observed at the original launch of the NovaSeq 6000 several years back. As you noted, with the 50 orders we already have in hand from that initial batch, our Q1 shipments are entirely sold out. We're heading into the year in a genuinely solid spot as far as NovaSeq X deliveries go. There's also a robust queue of 170 customers already making their way through the process. So if you consider the unit figure for the year — the 300 I mentioned — it's obvious that availability of supply, rather than demand, will be the bigger limiting factor on how many we ship next year. As you mentioned, we're starting this year with an extremely robust order book. Our view is that during the first two quarters, demand will outpace what we're able to deliver, since we're still increasing production capacity for NovaSeq X. Then, as we move into the latter half of the year, we'll begin working through that backlog.

Vijay Kumar

analyst
#8

Francis, I've got two parts to this, if that's okay, focused on the earlier Nova X. Let me lay out the constraints I want to bring up. Could you shed some light on how the current cycle stacks up against the earlier NovaSeq X? What I mean is, roughly a month has passed since a product announcement, and we're past 200 orders. From an order standpoint, this seems like it might be an enormous year for you folks next year. So perhaps draw the comparison with the earlier cycle, and then the Q4 guidance that's implied, this one's for Joydeep. Revenues, as I see them, are down 13%; and if I figure the first quarter of next year lands in negative territory, maybe the coming year works out to a mid-singles to high-singles top line. So whatever insight you can offer on how fiscal '22 might play out would be useful.

Francis deSouza

executive
#9

Yes, of course. I appreciate the question, Vijay. So, as I mentioned in response to the previous question, you're correct that customer response to NovaSeq X is definitely even more powerful than what we'd projected; and we'd based our projection on our earlier launches, which were extremely strong. Yet when we consider how many orders are already in hand, the 50 orders we have; the 170 sitting in the advanced pipeline. If I were to place that against where we stood at a comparable point with earlier launches, I'd say our position is stronger than it was with certain other earlier launches. So we're definitely in a very robust position as we head into next year. Once again, looking at next year, the quantity of NovaSeq shipments is going to be limited by supply. And we brought up a completely new manufacturing line, since we've reworked every single component of this instrument, correct? So completely new chemistry, new FFM, new flow cells, a new manufacturing process for the flow cells; and so the way that scale-up is proceeding makes us really pleased. So if I set the figure I provided for Q1 shipments against it, that would be ahead. So the 40 to 50 shipments we anticipate in Q1, that would exceed the shipments we made in the first quarter when we launched the NovaSeq 6000, so somewhat ahead of where we stood previously. And after that, the 300 units we expect to ship would also be ahead of where we were in the first year of NovaSeq x 6000; so that's the comparison with earlier launches. Perhaps I'll hand things over now to Joydeep.

Joydeep Goswami

executive
#10

Yeah, perhaps only one point regarding what has shifted when it comes to NovaSeq, correct? As Francis said before, we're observing robust demand — and notably strong early demand — coming from clinical customers too, right? That, in our view, stems from the ongoing pattern of solid clinical research activity, which for certain studies is now migrating over to NovaSeq X. So I'd call that a favorable development. I believe your following question concerned the connection with — for Q4 and afterward going into 2023. So regarding Q4, a couple of points: as we highlighted, right, near the close of Q3 and in the first part of October, we witnessed a worsening of certain macroeconomic circumstances we'd discussed, among them inflation and FX. That led us, for the reasons I gave before, to be cautious and adopt a more conservative stance in what we're forecasting for Q4, and beyond that we now anticipate these circumstances carrying on through 2023; so we're examining several of those circumstances. And as we're aware, certain elements have turned unfavorable. FX has unquestionably deteriorated and sped up on our end, and we anticipate it will remain a headwind as we move through 2023. I brought up the macroeconomic circumstances. We already noted that COVID surveillance will probably fall further during 2023. So these are among the elements tempering what we'd previously anticipated for — and still observe regarding interest in NovaSeq X, plus naturally a few of the other technologies we discussed at IGF, such as the Illumina complete long reads. Broadly speaking, Dan, I think our feeling right now — and bear in mind we haven't yet moved into guidance and budgeting — is that we likely expect revenue growth for 2023 to land nearer the 10% range instead of the figure we'd guided to previously.

Dan Arias

analyst
#11

Francis, could you briefly address the matter of the lab delays? During the prior quarter, it seemed as though those holdups were largely a second-quarter into third-quarter occurrence rather than not. This quarter, you hit your targets. Consequently, the projection for the fourth quarter is clearly being revised at this point, and that appears somewhat more stretched out than we'd anticipate. So could you explain what exactly is happening in that regard? Also, when do your forecasts anticipate a number of these labs will finally begin operating and reach the state they ought to be in?

Francis deSouza

executive
#12

Yes, certainly. During our previous discussion of the results on that call, we mentioned having observed certain postponements that we aimed to have ramped up before this year concluded, plus others slipping into the following year. What we discovered is that in each of those situations, things turned out somewhat later than what those customers had anticipated. As a result, we're witnessing a shift: what had been projected to arrive during this quarter is now being moved into the next year. Moreover, even the timelines for openings next year have been delayed to some degree as well. Thus, the effects tied to the pandemic involving the supply chain are certainly lingering and are creating an impact on those lab postponements.

Puneet Souda

analyst
#13

So, to begin with, I'd like some clarity on that 10% growth figure you brought up for 2023 — is that across the whole top line? And then I also want to dig a bit into the 10B and 25B flow cells. The 10B is coming out sooner, while the 25B arrives later next year. From where we sit, the 10 billion read flow cell looks like it could be the most significant piece in your lineup, since it can process samples within 24 hours and still provide the NovaSeq capacity that NovaSeq 6000 delivers today on an S4. So perhaps you could take us through how you expect that ramp to unfold? And what all of that implies regarding pull-through as we head into 2023.

Francis deSouza

executive
#14

Thanks, Puneet. Let me address both of those. First, I'd note that what we said regarding the 10% was not meant as guidance for the coming year. The intent was simply to describe how we're considering certain factors in play as Q4 moves into Q1, and once we've completed the bottoms of budget, we'll provide a specific guide as we enter next year. On the flow cells, I believe you're exactly right — in the sense that the first one, the 10 billion read flow cell, will be highly meaningful for customers seeking to become familiar with NovaSeq 6000 and comparing it against the instrument they already own, since it's quite similar in footprint and output, and it will likely handle some of the same workloads. As a result, customers will experience a sense of familiarity as they transition to the X with that flow cell. So you'll see customers beginning with that. After that, the $25 billion read flow cells are truly meant to open up the next generation of studies — the very large programs customers have discussed with us and have been awaiting, given the price points of the X that fundamentally make those studies possible. So you can view it this way: the first flow cell will strike existing NovaSeq 6000 customers as very familiar regarding output and the workloads it performs, and they'll begin using it as their entry point into the X series. Then the larger flow cell is what unlocks the next wave of elasticity in demand.

Joydeep Goswami

executive
#15

Dan, perhaps Puneet could chime in here as well. On the consumables front, we clearly anticipate that shift happening a good deal quicker among research and clinical customers, since those whose workflows are invalidated won't move over until somewhat further along in the cycle.

Julia Qin

analyst
#16

Francis, I recall that during Analyst Day you mentioned NovaSeq could serve as a significant catalyst for certain POPSEQ initiatives globally. Yet you also pointed out that in 4Q, some research projects would face delays, among them recruitment difficulties affecting particular POPSEQ programs. Given that, how significant should we expect the POPSEQ programs to be regarding their contribution to our revenue next year?

Francis deSouza

executive
#17

Sure. I'll take on both aspects of what you asked. First, the impact we're observing in Q4 concerning certain POPSEQ programs. Second, how the X will enable upcoming POPSEQ programs and just how crucial that will prove. Regarding Q4, we indicated that a limited number of quite specific population sequencing efforts currently underway are running into recruitment slowdowns tied to those efforts. It's just a small group, and they're seeing setbacks in these active projects; we're fully confident these projects will move forward, reach completion, and secure the recruitment they intended. However, things are moving somewhat more slowly in Q4 than anticipated. Now, considering what the X makes possible, that represents the following generation, so to speak; what customers have discussed with us for some time, and then seriously during the 5 weeks since we unveiled the X, are the really massive projects they wish to undertake. In these, sample counts sometimes reach into the millions. They're discussing extremely large exome efforts and extremely large genome efforts that, honestly, simply weren't financially feasible before we launched the X. One point we highlighted at Investor Day that applies here is that our team sometimes has a key role in facilitating those projects. So beyond acting as a technology enabler by delivering a scalable instrument at price points that render these projects feasible — in many instances, we also assist in assembling the relevant parties, be they pharmaceutical firms, biobanks, or national health systems; we take on the job of helping gather those parties to launch those projects. And I can share that during recent weeks, Susan and our commercial group have been extremely occupied with strong demand from health systems worldwide that want to harness the X's capabilities to build programs aimed at creating, for instance, cohorts far more diverse than what exists now or far larger than current ones; thus I believe the X will prove a major needle mover in that regard.

David Westenberg

analyst
#18

Our following question comes from David Westenberg at Piper Sandler. Apologies for picking up where I left off last quarter regarding how consumables get ordered. I realize many of these items typically carry an expiration date, and I recall you saying, Joydeep, that some of those ongoing dynamics related to burn down would stretch into Q4. Perhaps that lines up fairly closely with what you anticipated, yet when I compare it against my own model, it appears to be among the factors that keep showing up. So how should we avoid reading this as a deceleration for sequencing or for the broader market, especially considering many of your customers have budgets? They've got NIH budgets coming through. They have tests that need to be ordered, and what I'm really asking is: if this isn't the cause, why are we still looking at 10% in 2023, given that I'd assume there would be some catch-up from all those consumables that were missed during Q3 and Q4? And apologies if that question ran quite long.

Francis deSouza

executive
#19

Yes. Allow me to attempt to respond, and once more, as Francis stated, the budget process remains underway. So that 10% was never intended as guidance. It's closer to a reflection of the macroeconomic conditions we're observing. I think there are maybe 2 parts to this, David. First, regarding your question about whether we're seeing inventory deleveraging accelerate or decelerate — we actually matched what we had anticipated quite closely when it comes to inventory deleveraging, with perhaps a very minor portion of the extra guidance we gave on Q4 truly stemming from additional inventory deleveraging; that covers part one. Now, as to whether things have slowed — slowed down, rather — relative to what we communicated at the close of Q2: we did observe 2 specific items we called out, which had been slower than anticipated on our side, in terms of demand or activity. One involved the few key customers, a handful of customers Francis referenced, who had those large research and PopGen projects that ran into some recruit issues. Those, we believe, will cut — will recover in time. This isn't a budget problem; this isn't primarily an inflation related — not an inflation-related problem. The other item we observed was tied to inflation and FX, specifically affecting research customers in Europe. There, we did witness a slowdown occurring. We anticipate some of this will carry into next year as several of these headwinds remain; but once more, this isn't a structural shift; it's a temporary shift driven by very specific macroeconomic factors.

Michael Ryskin

analyst
#20

Great. I'll attempt to fit in a few, though they all concern the same subject. First, regarding the GRAIL write-down, that $3.91 billion. Could you walk us through the reasoning, the fundamental cause we've recorded it during this quarter? Does it affect any divestment talks, or the various pluses and minuses that feed into such a choice, particularly when you look back twelve months, since I believe the transaction happened roughly a year ago at $8 billion? And separately, did you explain how GRAIL declined sequentially, from $12 million in Q2 to $10 million in Q3, yet the fiscal year midpoint stayed roughly unchanged? So was that merely a few uneven orders arriving? Or what exactly is happening there?

Joydeep Goswami

executive
#21

Yes; allow me to address the first portion of what you asked. The revaluation of GRAIL's book value was essentially an accounting obligation set off by certain regulatory rulings emanating from Europe. Once more, the main factor behind the valuation shift was a greater discount rate applied, truly stemming from today's capital and equity market circumstances, correct? The underlying — GRAIL's performance regarding its progress on clinical outcomes and enrolling customers truly hasn't shifted, and actually has gotten somewhat better across the recent quarters. The impairment, once more, is an accounting adjustment, it carries no effect on our pursuit of different alternatives regarding GRAIL, and those continue just as we outlined previously during our — at our Investor Day. I'll hand it over to Francis.

Francis deSouza

executive
#22

Yeah, regarding that GRAIL figure. The way things unfolded over the quarter, July — that opening month — saw sluggish test ordering; after that, activity accelerated significantly in September, partly because of the sales team expansion GRAIL has implemented, which we discussed during the Q2 call. So that investment has delivered results during the final month of the prior quarter and through the initial weeks of the current one. That's what's shaping the curve. As for what we expect for the year, Q4 has begun strongly and the midpoint of guidance hasn't changed. Then there's another element at work in Q4: the revenue coming in from pharma partnerships tied to their MRD development.

Kyle Mikson

analyst
#23

Let me ask a quick question about the mortgage side of things. Regarding NovaSeq X, what are your near-term expectations for trade-ins and bundles, given that the X is essentially equivalent to several 6000 units? Could you perhaps discuss that alongside the '23 shipment figures you shared today and maybe referenced earlier? Then, Francis, separately, could you share your perspective on the complete offering in long-read sequencing, especially with the recent updates from Pac Bio and others?

Joydeep Goswami

executive
#24

Sure. I'll address the trade-in expectations first. Our customers, from what they've experienced with us, understand we've consistently assisted in maintaining customer <<inaudible>> whenever a new platform launches; thus, just as we've always operated at new platform launches, we offer trade-in options for those who bought 6,000 recently. We've actually set up a program right now so that if you purchase a 6,000 today to begin, you're able to trade it in — meaning buy now and exchange it once the X launches next year; and definitely, some customers have really valued that and participated; we anticipate additional ones will join through this quarter and into next year. That's a routine component of introducing a new product. As for our complete long reads, customer feedback has been highly enthusiastic about leveraging their current installed base across different throughput sizes. So whether you have a MiSeq, up to NovaSeq 6000 or the X, to handle both long-read and short-read applications and do so in a manner that lets them benefit from low sample inputs below what they might achieve on competing platforms. We anticipate that will be fundamentally enabling for that area; and if you — particularly if you merge your existing platforms with the complete long read plus enrichment, you gain the capacity to perform long reads far more cost effectively than on other platforms while not sacrificing accuracy at all. Thus you retain the gold standard of accuracy and can achieve it far more cost effectively. That's genuinely thrilling. It unlocks that final portion of the genome, the last few percentage of the genome that was traditionally difficult to read using short read technology.

Tejas Savant

analyst
#25

Francis, I've got two questions for you. First, I'd like to discuss the metered ramp down on NovaSeq 6000 consumables that you mentioned at the Analyst Day, which stems from a larger share of clinical users. Yet today, you noted a higher clinical mix for the X. I'm trying to reconcile these two things as we consider how NovaSeq 6000 consumables decline across the coming couple of years. My second question concerns some of the PopGen recruitment delays you mentioned. If my memory serves, during the prior product cycle, POPSEQ essentially had to come out of the guide since its timing became so hard to predict. Could you point to what's different now that gives you confidence that, at least when it comes to POPSEQ, you'll keep seeing that kind of demand elasticity?

Francis deSouza

executive
#26

Yes, excellent question. Let me address the first one. You're completely correct that if you're running production clinical workloads at present, you'll keep running them on the NovaSeq 6000 for some time. After that, there will be a metered transition, measured in quarters and years, before that entire production workload shifts over to the X. That remains our belief, and it remains the feedback our customers are giving us. What's truly exciting, however, is that clinical customers are discussing with us — and their purchases are centered on — new workloads. These are areas they wish to expand into, and they're telling us that rather than beginning on the 6,000, they'd prefer to start that development on the X, with the intention, naturally, of scaling it into production on the X. That has been more substantial than we anticipated, which means a number of our large clinical customers are expanding into new clinical areas. It's an exciting development for the field, and it's also an exciting development for X. Regarding POPSEQ, what we've said is that whenever we bring on new POPSEQ deals — new large POPSEQ deals — we'll generally binary them out of our guide if they're big and we're still working out when they'll land. As you're aware, that's a lesson we learned about how these deals develop. But once they're in production, they're in the guide, correct? So there, the variability isn't as large as whether a big deal will come on or not. It could go higher or lower within a quarter, and if that occurs, or if we begin to see it occurring, we will definitely flag it for you — that is exactly what we are doing for Q4. So that is more a matter of reduced variability rather than a completely new deal arriving, and once again, when it comes to factoring that into our guide, we will generally lean toward being more conservative.

Joydeep Goswami

executive
#27

And Francis, let me just jump in here — I think this is a really good question on the clinical side, isn't it? I think what we're seeing is that a number of those newer tests Francis mentioned are shifting more toward NovaSeq X, since these are also the more intense tests, and they come with much greater throughput needs, which lines up with what we said about demand elasticity that keeps rising as new technologies come in.

Dan Leonard

analyst
#28

Let me just check that I've got this right regarding the revised 2022 outlook for Core Illumina. From what I can tell, you tied half of that cut to X-related delays — if my calculation is correct, that's 70% of the 2/3 — and you already knew the X was coming. So what turned out differently than you'd expected?

Francis deSouza

executive
#29

Correct, that's exactly it. The X launch was something we were aware of going in, and our assumptions about how much customers would want it were built from prior launches we'd been through. Honestly, the level of customer enthusiasm for moving to the X has caught us off guard in a good way. And to repeat what I mentioned earlier, we'd assumed our clinical customers would take somewhat longer to get on board with the X. What we're actually seeing is that the factors we described aren't behind it — while these customers continue running production workflows on the 6,000, they're eager to apply the X to their new applications, which, as Joydeep noted, are typically the more sequencing-intensive ones. So the excitement around the X has been a pleasant upside, yet it creates a knock-on effect, with customers telling us they'll pause on the 6,000 during Q4 and instead wait for the X once it begins shipping in Q1.

Patrick Donnelly

analyst
#30

Patrick, one question about the customer base, specifically on the clinical diagnostics side. In the prior quarter, as I recall, you mentioned they were being somewhat more cautious regarding cash, especially in relation to the inventory matter. Is that trend still present in your view? How are those discussions going, and what does the outlook look like for that market during '23?

Francis deSouza

executive
#31

Yes, thank you, Patrick. That is absolutely still unfolding as we expected. In our view, 2 dynamics are at work. First, activity levels measured by runs performed on the instruments they own remain strong and are broadly consistent with what we described in Q2. Second, we are observing anxiety regarding their cash situation, along with our preference for helping them keep inventory levels leaner than has traditionally been the case; that is also made possible because they have witnessed how steady, strong, and reliable our supply has been, including throughout the pandemic. We feel confident telling them that we can operate with reduced inventory for some time while preserving the integrity of their operational capability. So that pattern is clearly still with us.

Luke Sergott

analyst
#32

Could you help us understand what kind of margin profile XLEAP will deliver? I believe this matters a lot when you're scaling up NovaSeq X during the coming year, and as that keeps growing and you get increased pull-through, we should try to determine what the operating margin will end up being?

Francis deSouza

executive
#33

Absolutely, Luke. Our expectation, and the way we've designed it, is that instruments employing the new XLEAP chemistry will keep margins comparable to those of the instruments being replaced. Take the X as an illustration — over time, as it expands, you ought to view it as having a margin profile much like the NovaSeq 6000, both broadly for the instrument itself and definitely for consumables; that's the design criterion we apply. The concept is to put money into technology that essentially reduces how much it costs to manufacture the product, and afterward hand those savings over to our customers. So we hold margins steady and give our customers the savings tied to the innovations we're introducing, such as X, such as the new optics, such as the new flow cells, and so forth.

Jack Meehan

analyst
#34

I'd like to spend a moment on the fourth-quarter guidance. As I figure it, the updated consumables outlook works out to flat for the year — feel free to verify that against the earnings slide. That would suggest a 16% decline in Q4, in my view. Could you walk us through the dynamics at play, perhaps splitting price versus volume? And considering you're describing this as somewhat concentrated within one portion of the customer base, it strikes me as a sizable swing.

Joydeep Goswami

executive
#35

Sure. Jack, regarding the entire year, your assessment is correct — the pattern for consumables is trending toward flat. On pricing, there's really no effect, correct? Volume is essentially the driver here, though we do monitor the pricing element quite closely, and it aligns with prior quarters. The causes behind the lower volume match what we communicated before, correct? So part of it stems from that. Incidentally, when you examine revenues, a portion reflects FX that has flowed through. Then on the volume side, you have two elements, correct? Mainly there's an inventory deleveraging piece, which we experienced — most of which was flagged previously — plus there's a further portion. And then the two particular items involving big research customers, hiring delays, and some deceleration tied to inflation and FX that we've observed in Europe. Those remain the biggest drivers of the deceleration. And another point Francis raised too concerns the NovaSeq X side, correct? Greater interest in NovaSeq has pushed back certain consumables buys for NovaSeq X too, correct? So that factors in as well.

Sallilyn Schwartz

executive
#36

We appreciate everyone being with us on this call. Just a note that you'll be able to find a recording of today's session over in the Investors area of our site; that wraps things up for us, and we're eager to reconnect with all of you for our next update at the JPMorgan Healthcare Conference in January.

Operator

operator
#37

Appreciate it. That brings today's call to a close. Thanks so much for joining us. Have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.